Although these fusions are rare in glioblastoma, the incidence in the Combined cohort being 0.5% for ST7–MET and LMNA–NTRK1, 1.1% for PTPRZ1–MET and GOPC–ROS1, and 1.6% for FGFR3 fusions [7], they appear to be targetable alterations that also occur in other solid cancers [36]. Here, MET is linked to glioblastoma.